Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 in Pediatric Wilson Disease
NCT05047523Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Started Sep 2021; status: terminated.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT05047523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047523.